Ruetsche AG, Lippuner K, Jaeger P, Casez JP (2000) Differences between dual X-ray absorptiometry using pencil beam and fan beam modes and their determinants

in vivo and in vitro. J Clin Densitom 3:157–166CrossRefPubMed 16. Griffiths MR, Noakes KA, Pocock NA (1997) Correcting the magnification error of fan beam densitometers. J Bone Miner Res 12:119–123CrossRefPubMed 17. Hwua Y-S, Huang B-Y, Hua M-Y, Wen H-W (2008) Differrece in the spinal bone mineral density measured with and without hip flexion. J Clin Densitom 11:453CrossRef 18. Nord R, Ergun D, Faulkner K (2002) Effect of patient positioning devices on bone density measurements. J Bone Miner Res 17:313 19. Formica CA (1998) Standardization of BMD measurements. Osteoporos Int 8:1–3CrossRefPubMed”
“Introduction https://www.selleckchem.com/products/Belinostat.html The incidence of venous thromboembolism (VTE) varies according to the presence of a number of risk factors; selleck products most notable are age, immobilisation, hospitalisation, and surgery [1, 2]. In addition, ageing

is accompanied by an increasing incidence of chronic diseases, which can impair general health status, and may also indirectly increase the risk for VTE [3]. One such chronic disease is osteoporosis, which leads to an increased risk for fracture, especially when it is associated with other risk factors, such as age, sex, history of fractures, low body mass index (BMI), or a recent fall [4–6]. The occurrence of osteoporotic fracture may in turn lead to immobilisation,

hospitalisation, and surgery. By accumulating risk factors, ageing osteoporotic patients may, therefore, be particularly susceptible to VTE, though this has never Methane monooxygenase been demonstrated. The most commonly used agents to treat osteoporosis are selleck chemicals llc bisphosphonates, calcitonin, raloxifene, parathyroid hormone, and strontium ranelate [7–10]. Analyses of the pooled populations of phase III studies for strontium ranelate have shown a slight increase in the annual incidence of VTE, with a relative risk of 1.4 (95% confidence interval [CI], 1.0–2.0) versus placebo [11]. However, this increased risk with strontium ranelate remains weak when compared with treatments with a clear biological rationale for increasing VTE, such as selective oestrogen–receptor modulators or oestrogen replacement treatment [12–15]. The objectives of this study were to explore the incidence of VTE and its risk factors in osteoporotic and non-osteoporotic women and to investigate the relationship between the incidence of VTE and the anti-osteoporotic treatments strontium ranelate and alendronate sodium. Alendronate sodium is the most highly prescribed bisphosphonate in the UK and has never been associated with an increased risk for VTE. Methods Data source The General Practice Research Database (GPRD) contains anonymous electronic medical records from primary care in the UK. It encompasses a representative sample of approximately 6% of the population from around 450 practices throughout the UK.